

Ist. Farm. Biologico Stroder | Istituto De Angeli | Istituto Ganassini | Istituto Gentili | Istituto Luso Farmaco d'Italia | Italcimici | Italfarmaco | Italia | ITEL Telecomunicazioni | Johnson & Johnson Innovative Medicine | Johnson & Johnson Medical | Kedrion | Kyowa Kirin | L. Molteni & C. F.lli Alitti | Laboratori Baldacci | Laboratori Guidotti | Laboratorio Farmaceutico C.T. | Laboratorio Farmaceutico S.I.T. | Laboratorio Terapeutico M.R. | Latina Pharma | Leo Pharma | Lifepharma | Lofarma | Lundbeck Italia | Luxpharma | Malesci Istituto Farm. | Mastelli | Master Pharma | Menarini Biotech | Merck Serono | Mercurio Pharma | Mitim | Moderna Italy | Monico | Morganceutical | MSD Italia | Mundipharma Pharmaceuticals | Neopharmed Gentili | Nerviano Medical Sciences | Noos | Norgine Italia | Novartis Farma | Novo Nordisk | Octapharma Italy | Omikron Italia | Otsuka Pharmaceutical Italy | Patheon Italia | Pfizer Italia | Pfizer | Pharmanutra | Philogen | PIAM Farmaceutici | Pierre Fabre Pharma | Pierrel | Polichem | Polifarma | Promedica | Recordati Ind.Chim.Farm. | Recordati Rare Diseases Italy | Roche | Sanofi | Santen Italy | Savio Industrial | Scharper | Servier Italia | Shionogi | SIFI | Simesa | So.Se.Pharm | Società Prodotti Antibiotici | Sofar | Stewart Italia | Swedish Orphan Biovitrum | Takeda Italia | Takeda Manufacturing Italia | Temmler Italia | Teva Italia | Theramex Italy | Tillotts Pharma Italy | UCB Pharma | Vertex Pharmaceuticals | Viatrix Italia | ViiV Healthcare | Vim G. Ottaviani | Visufarma | Wyeth Lederle | Zambon | Zeta Farmaceutici

# PHARMACEUTICAL INDUSTRY IN ITALY

## FACTS AND FIGURES

## MEMBER COMPANIES

A.C.R.A.F. Az Chim. Riunite Angelini Francesco | A. Menarini Ind. Farm. Riunite | Abbvie | Abiogen Pharma | Acaripa Farmaceutici | Adare Pharmaceuticals | Addenda Pharma | Advanced Accelerator Applications Italy | Aeffe Farmaceutici | Aesica Pharmaceuticals | Alexion Pharma Italy | Alfasigma | Alk-Abelló | Allergan | Almirall | Alnylam Italy | Altergon Italia | Amgen | Aptuit | Astellas Pharma | Astrazeneca | Aurora Biofarma | Avara Liscate Pharmaceutical Services | Bausch & Lomb Iom | Baxter Italy | Bayer Healthcare Manufacturing | Bayer | Bial Italia | Biogen Italia | Biologici Italia Laboratories | Biopharma | Boehringer Ingelheim Italia | Bracco Imaging | Bristol-Myers Squibb | Bruschetti | BSP Pharmaceuticals | C.O.C. Farmaceutici | Catalent Italy | Chiesi Farmaceutici | Chiesi Italia | Corden Pharma | Cosmo | Crucell Italy | CSL Vifor | CSO Pharmitalia | D.M.G. Italia | Daiichi Sankyo Italia | Dompé Farmaceutici | Doppel Farmaceutici | Ecupharma | Eisai | Eli Lilly Italia | E-Pharma Trento | Esseti Farmaceutici | Euromed | F.I.R.M.A. | Farmaceutici Damor | Farmaka | Farmalabor | Farmila-Thea Farmaceutici | Fatro | Ferring | Fine Foods & Pharmaceuticals N.T.M. | Fulton Medicinali | Galderma Italia | Galileo Research | GB Pharma | GE Healthcare | Gentium | Gilead Sciences | Giuliani | Glaxosmithkline Manufacturing | Glaxosmithkline | Glaxosmithkline Vaccines | Glenmark Pharma | Grifols Italia | Grünenthal Italia | Guerbet | Hikma Italia | I.B.I. Giovanni Lorenzini | I.B.N. Savio | IBSA Farmaceutici Italia | IDI Farmaceutici | Incyte Biosciences Italy | Ind. Farm. Galenica Senese | Ipsen | Iqvia Solutions Italy |



FARMINDUSTRIA

### FARMINDUSTRIA

Largo del Nazareno 3/8 - 00187 Roma

T: 06 675801

Avenue de la Joyeuse Entrée 1 - B1040 Bruxelles

T: +32 2 2861255

farmindustria@farmindustria.it

www.farmindustria.it



Publication closed with data and information  
available as of 19/06/2026



FARMINDUSTRIA



# Research and Innovation for People

## GROWING HOPE FOR TREATMENT

### WORLDWIDE

**78** new medicines authorized on average over the last three years (58 was the annual average in the previous decade)

**23 K** new medicines under development

**6 lives per minute** saved thanks to vaccines over the last 50 years

**Growing hope** for new treatments, with medicines becoming increasingly personalized for patients

## LIVING LONGER AND BETTER

### IN ITALY

**-31%** mortality over the last 25 years

**-41%** mortality from chronic diseases

over the last 25 years

**+ 1 million** people surviving after a cancer diagnosis over the last 10 years

**290 k** people cured thanks to innovative medicines for Hepatitis C by 2026

**275+** medicines currently authorized by EMA for rare disease (there were 7 in 2007)

## THE CLOCK OF LIFE

**+1 year** of average life expectancy over the last three years thanks to research, to more appropriate care and to quality of the National Health Service



# People, Our Strength

## HIGH-QUALITY EMPLOYMENT

**72.200** employees

**90%** university graduates or high-school graduates

**45%** women (29% industrial average),

often in senior management positions

**+10%** employment vs 2019 (+5% national average)

**316 K** people employed, including the direct supply chain and other sectors of the value chain

## YOUNG PEOPLE AND TRAINING

**+25% under 35** vs 2019

Increasing involvement in training and professional development activities, with a particular focus on multidisciplinary and soft skills

## CORPORATE WELFARE FOR PEOPLE

**Work life balance** is increasingly at the heart of companies' policy, promoting work-life balance, physical and mental wellbeing, support for parenthood and caregivers, valuing diversity, training and health



# Creating Value in Italy

## PRODUCTION AND VALUE ADDED

**European leader** and a strategic asset for the economy

**Around 200** companies with more than 130 manufacturing sites

**€ 74 billion** in production value in 2025

**+11%** productivity above the average of the pharmaceutical industry in the major EU countries

## EXPORTS

**€ 69,2 billion** in 2025 (+28,5% vs 2024)

**+248%** over the last ten years (+148% EU average)

**11,3%** share of Italy's manufacturing exports in 2025

**€ 11,4 billion** trade surplus in 2025

## INVESTMENTS IN R&D AND MANUFACTURING

**€ 4,4 billion** invested in 2025 in Italy: € 1,9 billion

invested in high-technology manufacturing facilities and

€ 2,5 billion in R&D (including more than € 800 in hospital-based

**clinical research**, generating benefits in access to new

treatments, skills development and savings for the

National Health Service)

**+26%** average patent applications over the last five years

(+10% average in the major EU countries)

**1<sup>st</sup>** in Italy for Open Innovation (14:1 ratio of Open

Innovation investments per employee compared with the

manufacturing average)



# Leading Change

## GREATER ATTRACTIVENESS TO DRIVE GROWTH

**\$ 2.1 trillion** in R&D investments worldwide between 2027 and 2032. A **growth** opportunity that Italy must seize through attractive policies that enhance its scientific and industrial excellence

## DIGITAL TRANSFORMATION

**53%** of Italians access their Electronic Health Record (EHR) (+13 percentage vs 2025)

**62%** of healthcare facilities have introduced a telemedicine consultation service

**77%** hospital physicians use Electronic Medical Records (EMRs)

**59%** of pharmaceutical companies use AI to design clinical trials

## GREEN TRANSITION

Among the **leading** manufacturing sectors in **environment sustainability initiatives**, including: improved energy efficiency, use of renewable energy, reduced water consumption and

eco-design of secondary packaging

**-30%** energy intensity over the last ten years

(-16% manufacturing average)

**-37%** greenhouse gas emissions intensity over the last ten

years (-21% manufacturing average)